In our study, patients with LC3 expression in both the tumor and liver microenvironments (+/+) had a better clinical outcome than those lacking LC3 expression in both tissue types (-/-), in the HCC tissue alone (-/+), and in the liver microenvironment alone (+/-). Here, MAP1LC3A is linked to hepatocellular carcinoma.